Combination treatment of hypertension in 2015
We present an overview of the present views on combination treatment and on fixed combinations in the treatment of hypertension according to guidelines of ESH/ESC and ČSH from 2013. The most frequently recommended dual combinations include a blocker of the renin-angiotensin system (ACEI or sartan) and a calcium channel blocker, and further a blocker of the renin-angiotensin system and a diuretic and a calcium channel blocker and a diuretic. In 2014 a fixed-dose combination of an ACE inhibitor (perindopril), a calcium channel blocker (amlodipine) and an diuretic (indapamide) appeared on the Czech market. Within the PIANIST study including 4 731 insufficiently controlled hypertensives, a fixed-dose triple combination of perindopril, amlodipine and indapamide led to a decrease in blood pressure by 28.3/13.8 mm Hg and to a sufficient control of hypertension in 92 % of patients. The advantage of fixed combinations primarily consists in greater compliance of patients and thereby in a better control of hypertension. About 1/3 of hypertensives need a triple combination for a satisfactory blood pressure control..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2015 |
|---|---|
| Erschienen: |
2015 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:61 |
|---|---|
| Enthalten in: |
Vnitřnı lékařství - 61(2015), 5, Seite 458 |
| Sprache: |
Tschechisch |
|---|
| Beteiligte Personen: |
Špinar, Jindřich [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antihypertensive Agents - therapeutic use |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
OLC1962135306 |
|---|
| LEADER | 01000caa a2200265 4500 | ||
|---|---|---|---|
| 001 | OLC1962135306 | ||
| 003 | DE-627 | ||
| 005 | 20230508123451.0 | ||
| 007 | tu | ||
| 008 | 160206s2015 xx ||||| 00| ||cze c | ||
| 028 | 5 | 2 | |a PQ20160617 |
| 035 | |a (DE-627)OLC1962135306 | ||
| 035 | |a (DE-599)GBVOLC1962135306 | ||
| 035 | |a (PRQ)pubmed_primary_260758560 | ||
| 035 | |a (KEY)N0524285420150000061000500458combinationtreatmentofhypertensionin2015 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a cze | ||
| 082 | 0 | 4 | |a 610 |q DNB |
| 100 | 1 | |a Špinar, Jindřich |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Combination treatment of hypertension in 2015 |
| 264 | 1 | |c 2015 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 520 | |a We present an overview of the present views on combination treatment and on fixed combinations in the treatment of hypertension according to guidelines of ESH/ESC and ČSH from 2013. The most frequently recommended dual combinations include a blocker of the renin-angiotensin system (ACEI or sartan) and a calcium channel blocker, and further a blocker of the renin-angiotensin system and a diuretic and a calcium channel blocker and a diuretic. In 2014 a fixed-dose combination of an ACE inhibitor (perindopril), a calcium channel blocker (amlodipine) and an diuretic (indapamide) appeared on the Czech market. Within the PIANIST study including 4 731 insufficiently controlled hypertensives, a fixed-dose triple combination of perindopril, amlodipine and indapamide led to a decrease in blood pressure by 28.3/13.8 mm Hg and to a sufficient control of hypertension in 92 % of patients. The advantage of fixed combinations primarily consists in greater compliance of patients and thereby in a better control of hypertension. About 1/3 of hypertensives need a triple combination for a satisfactory blood pressure control. | ||
| 650 | 4 | |a Hypertension - drug therapy | |
| 650 | 4 | |a Antihypertensive Agents - therapeutic use | |
| 650 | 4 | |a Blood Pressure - drug effects | |
| 650 | 4 | |a Hypertension - physiopathology | |
| 700 | 1 | |a Vítovec, Jiří |4 oth | |
| 700 | 1 | |a Špinarová, Lenka |4 oth | |
| 700 | 1 | |a Bendová, Miroslava |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Vnitřnı lékařství |d Praha : Česká Lékařská Společnost Jana Evangelisty Purkyně, 1955 |g 61(2015), 5, Seite 458 |w (DE-627)166267376 |w (DE-600)138213-5 |w (DE-576)014611228 |x 0042-773X |7 nnns |
| 773 | 1 | 8 | |g volume:61 |g year:2015 |g number:5 |g pages:458 |
| 856 | 4 | 2 | |u http://www.ncbi.nlm.nih.gov/pubmed/26075856 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a GBV_ILN_4219 | ||
| 951 | |a AR | ||
| 952 | |d 61 |j 2015 |e 5 |h 458 | ||